Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. is located in the Nanjing High tech Industrial Development Zone. The company is a high-tech enterprise in Jiangsu Province and Nanjing City, and the chairman unit of the Heparin Sodium Branch of the China Chamber of Commerce for the Import and Export of Medical and Health Products. The company has established a nationwide, traceable and high-quality supply chain of heparin raw materials, mainly producing heparin sodium and low molecular weight heparin series products, ranking among the top in production and sales in the country, with heparin sodium production accounting for about 20% of the global production. The company's products have passed certifications such as Chinese GMP, US FDA, and EU EDQM, and are mainly exported to countries such as Europe and America. It has long-term cooperative relationships with multiple Fortune 500 pharmaceutical companies. According to the development plan, the company is further expanding its production capacity and output in the field of heparin sodium raw materials. In early 2005, the company officially undertook the construction task of the "Nanjing Mucopolysaccharide Biochemical Drug Engineering Technology Research Center" and passed the acceptance at the end of 2007. In 2012, it was upgraded to the "Jiangsu Mucopolysaccharide Biochemical Drug Engineering Technology Research and Development Center". The center relies on the company's research and development, technology, and laboratory equipment to improve the research conditions of mucopolysaccharides. It focuses on the research and development of enoxaparin sodium, dabarin sodium, nadroparin calcium, and heparinoids, actively promoting the industrialization of related scientific research achievements, and creating good economic and social benefits. In recent years, the company has established a development vision of "building a first-class international biopharmaceutical enterprise", constructed a sunshine culture, optimized the company's internal business management mechanism, and formed an advanced product research and development system, standardized production management system, and an international level quality management system; At the same time, a new formulation research and production base will be established in the high-tech zone, dedicated to the research and development of formulation products and the extension of the product value chain, creating the company's core competitiveness and striving to build a first-class international biopharmaceutical enterprise. |
| Headquarter | Nanjing |
| Establish Date | 10/16/2000 |
| Listed Code | 603707.SH |
| Listed Date | 7/19/2017 |
| Chairman | Tang Yongqun. |
| CEO | Tang Yongqun. |
| Website | www.nkf-pharma.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
